Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimasartan Dose-Finding Study in Mild to Moderate Essential Hypertension
NCT00923611Phase 2Completed
- Sponsor
- Boryung
- Start
- Sep 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fimasartan in essential hypertension (5 arms), sponsored by Boryung. Primary endpoint: Change in Sitting Diastolic Blood Pressure at 8 weeks. Started Sep 2007; status: completed.
02
Drugs
fimasartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00923611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923611.